Global CRO Reach HD Biosciences operates as a biology-focused preclinical CRO with facilities in Shanghai, San Diego, and Cranbury, enabling cross-regional project execution and rapid access for multinational clients seeking preclinical services.

Acquisition Advantage As a WuXi AppTec company since 2017, HD Biosciences benefits from integrated open-access platform capabilities and cross-sell opportunities within a larger pharmaceutical services ecosystem to expand client engagements.

Preclinical Expertise Specialization in target validation, pharmacology, hit discovery, lead optimization, and in vivo pharmacology positions HD Biosciences to win projects that require comprehensive early-stage drug discovery and robust data generation.

Mid-market Focus With revenue in the 10–25 million range and employee scale around 50–200, HD Biosciences targets mid-sized pharma and biotech firms seeking high-quality preclinical services, offering scalable engagement models.

Expansion Synergy Leverage potential cross-sell to WuXi AppTec’s broader lab services and client portfolio, including collaboration opportunities in target validation and in vivo pharmacology to deepen existing client relationships and win larger programs.